Windlas Biotech Limited — Updates, 12-11-2024: Press Release

Windlas Biotech Limited has reported strong financial performance for H1 and Q2 FY25. Revenue from operations reached ₹362.2 crores for H1, marking a 21.7% year-on-year growth, while Q2 contributed ₹187 crores, reflecting a 22.5% increase from the previous year. EBITDA also showed impressive growth, standing at ₹43.9 crores in H1 (up 22.6% YoY) and ₹23 crores in Q2 (up 23.3% YoY), with margins maintained at 12.1% and 12.3%, respectively. PAT rose to ₹29.1 crores for H1, an increase of 11.7% YoY, and ₹15.6 crores for Q2, up 11.5% YoY.

The company highlighted significant growth across its verticals, particularly in Trade Generics and CDMO segments, which remain crucial for their strategy. The steady cash flow of ₹30 crores and a robust liquidity position of ₹200 crores as of September 30, 2024, bolster Windlas Biotech’s outlook. The company’s recent capacity expansion efforts are expected to further enhance growth potential, making it a stock to watch closely.